MISSISSAUGA, ON, Sept. 17, 2012 /CNW/ - Sunovion Pharmaceuticals Canada
Inc. today announced that LATUDA™ (lurasidone HCl) tablets, a
once-daily atypical antipsychotic agent indicated for acute treatment
of adult patients with schizophrenia is now available by prescription
in pharmacies across Canada. LATUDA was approved by Health Canada on
June 13, 2012 and is available in 40 mg, 80 mg and 120 mg tablets.
LATUDA has been evaluated in 48 clinical studies involving more than
2,900 lurasidone-treated subjects.
"Schizophrenia is a devastating disease for those who suffer from it,
and deeply affects their families as well," said Dr. Ruth Baruch,
Medical Director of Community Programs, Department of Psychiatry,
Toronto East General Hospital. "The availability of LATUDA will provide
physicians with an important new treatment option to help manage the
illness and assist in improving the quality of life for individuals
The efficacy of LATUDA was established in five, 6 week placebo
controlled studies of adult patients with schizophrenia. In these
studies, LATUDA demonstrated significantly greater improvement versus
placebo on primary efficacy measures [change from baseline in Positive
and Negative Syndrome Scale (PANSS) total score and Brief Psychiatric
Scale-derived from PANNS (BPRSd)] at study endpoint. The most common
adverse events in patients treated with LATUDA were nausea, somnolence,
akathisia and parkinsonism.
"LATUDA is an important product for our company and we are excited to
offer this new treatment option to physicians caring for adult patients
with schizophrenia," said Douglas Reynolds, President, Sunovion
Pharmaceuticals Canada Inc.
Schizophrenia is a chronic, disabling disorder that is characterized by
symptoms such as hallucinations, delusions, disorganized thinking, lack
of emotion, lack of energy, as well as problems with memory, attention
and the ability to plan, organize and make decisions. This disease
affects approximately one percent of the population, which translates
to more than 335,000 Canadians. The goal of treatment is to reduce
symptoms, achieve stability, and facilitate illness improvement. While
there are several treatment options available, each patient responds to
their medications differently. A key obstacle is the ability to
tolerate medications and unfortunately treatment discontinuation in
this disease is as high as 40-50%2. Discontinuation is only partly due to intolerability; lack of efficacy
plays a large role. Effective treatment for each patient requires the
right balance of efficacy, safety and tolerability.
LATUDA (lurasidone HCl) is a new medication in the atypical
antipsychotic class that has been approved by Health Canada for the
acute treatment of adult patients with schizophrenia.
LATUDA has been studied in 48 clinical studies involving more than 2,900
lurasidone-treated subjects. The efficacy of LATUDA was demonstrated in
five, 6 week placebo-controlled studies, involving hospitalized
patients with schizophrenia. The efficacy of LATUDA for long-term use,
that is, for more than 6 weeks, has not been systemically evaluated in
controlled studies. LATUDA was associated with low rates of change in
metabolic parameters versus placebo. The most common adverse events in
patients treated with LATUDA were nausea, somnolence, akathisia and
For Important Information Concerning LATUDA go to www.sunovion.ca
About Sunovion Pharmaceuticals Canada Inc.
Sunovion Pharmaceuticals Canada Inc. is focused on the development and
commercialization of prescription products in Canada. In addition to
commercializing Sunovion Pharmaceuticals Inc.'s products, our strategy
is to license pharmaceutical products that meet the needs of patients
and the Canadian health care system, currently focusing on
cardiovascular disease, infectious disease and central nervous system
(CNS) disorders. More information about Sunovion Pharmaceuticals
Canada Inc. is available at www.sunovion.ca
Sunovion Pharmaceuticals Canada Inc., a subsidiary of the U.S. based
Sunovion Pharmaceuticals Inc., is headquartered in Mississauga,
Ontario. Sunovion Pharmaceuticals Inc., an indirect, wholly-owned
subsidiary of Dainippon Sumitomo Pharma Co., Ltd., is headquartered in
Marlborough, Mass. More information about Sunovion Pharmaceuticals
Inc. is available at www.sunovion.com.
About Dainippon Sumitomo Pharma Co., Ltd. (DSP)
DSP is a multi-billion dollar, top-ten listed pharmaceutical company in
Japan with a diverse portfolio of pharmaceutical, animal health and
food and specialty products. DSP aims to produce innovative
pharmaceutical products in the CNS field, which has been designated as
the key therapeutic area and will also focus in on other specialty
disease categories with significant unmet medical needs, which are
designated as frontier therapeutic areas. DSP is based on the merger in
2005 between Dainippon Pharmaceutical Co., Ltd., and Sumitomo
Pharmaceuticals Co., Ltd. Today, DSP has more than 7,000 employees
worldwide. Additional information about DSP is available through its
corporate website at www.ds-pharma.com.
LATUDA is a registered trademark of Dainippon Sumitomo Pharma Co., Ltd.
1 Public Health Agency of Canada, Available at: http://www.phac-aspc.gc.ca/publicat/miic-mmac/chap_3-eng.php. Accessed June 11, 2012.
2 IMS Brogan, March 2012
For a copy of this release or any recent release, visit Sunovion's web
site at www.sunovion.ca
SOURCE: Sunovion Pharmaceuticals Canada Inc.
For further information:
Sunovion Pharmaceuticals Canada Inc.
Senior Director, Corporate Communications
Sunovion Pharmaceuticals Inc.